This activity has expired. Credit is no longer available.
This activity was supported by educational grants from Bristol-Myers Squibb Company; Genomic Health, Inc.; and Merck Sharp & Dohme Corp.
Precision Oncology Comes of Age: Tumor-Agnostic Approaches
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute of Emory University
Colleen Lewis, MSN, ANP-BC, AOCNP
Winship Cancer Institute of Emory University
Guided by two experts in the field, dive into the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support the advancement of precision medicine.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |
in collaboration with
  |